美好医疗回复：尊敬的投资者您好！人工植入耳蜗是脑机接口的重要应用方向，也是当前临床应用中最 为成功的技术典范之一，其设计寿命可支持长期乃至终身使用。公司作为全球人工植入耳蜗龙头企业的 战略合作伙伴与核心供应商，在人工植入耳蜗组件的工艺研发与生产转化，与客户有近15年的深度协 作。侵入式脑机接口产品在植入体材料选型、生物相容性要求、生产工艺、品质系统控制等关键工艺技 术领域与人工耳蜗高度相通。公司正与下游创新型脑机接口客户深入开展工艺探索和技术合作，协助客 户实现从实验室研发到批量出货的高效商业化转化。目前，公司脑机接口业务产生的收入规模较小，请 注意相关风险。感谢您对公司的关注！ 证券之星消息，美好医疗(301363)01月14日在投资者关系平台上答复投资者关心的问题。 投资者提问：马斯克旗下美国脑机接口公司Neuralink将于2026年开始大规模生产脑机接口设备并完成新 轮融资，请问公司与Neuralink有无业务合作及关联？如有业务合作，请问公司具体向Neuralink有哪些核 心部件供应？ 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 ...

每经AI快讯，有投资者在投资者互动平台提问：马斯克旗下美国脑机接口公司Neuralink将于2026年开 始大规模生产脑机接口设备并完成新轮融资，请问公司与Neuralink有无业务合作及关联？如有业务合 作，请问公司具体向Neuralink有哪些核心部件供应？ 美好医疗（301363.SZ）1月14日在投资者互动平台表示，人工植入耳蜗是脑机接口的重要应用方向，也 是当前临床应用中最为成功的技术典范之一，其设计寿命可支持长期乃至终身使用。公司作为全球人工 植入耳蜗龙头企业的战略合作伙伴与核心供应商，在人工植入耳蜗组件的工艺研发与生产转化，与客户 有近15年的深度协作。侵入式脑机接口产品在植入体材料选型、生物相容性要求、生产工艺、品质系统 控制等关键工艺技术领域与人工耳蜗高度相通。公司正与下游创新型脑机接口客户深入开展工艺探索和 技术合作，协助客户实现从实验室研发到批量出货的高效商业化转化。目前，公司脑机接口业务产生的 收入规模较小，请注意相关风险。 （记者 王晓波） ...

证券之星消息，美好医疗(301363)01月14日在投资者关系平台上答复投资者关心的问题。 投资者提问：请及时回复1月10日之股东人数。感谢！ 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 美好医疗回复：尊敬的投资者，截至到2026年1月9日，公司股东总户数为42,300户。 ...

美好医疗回复：尊敬的投资者，截至到2026年1月9日，公司股东总户数为42,300户。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，美好医疗(301363)01月14日在投资者关系平台上答复投资者关心的问题。 投资者提问：请问，截至2026年一月 9日公司的股东总数是多少？谢谢 ...

Core Viewpoint - The company, Shenzhen Meihao Chuangyi Medical Technology Co., Ltd., is focusing on the development and commercialization of medical devices, particularly in the fields of brain-machine interfaces, PEEK materials, and CRO services, while benefiting from the depreciation of the RMB [2][4]. Group 1: Business Overview - The company's main business involves the design, development, manufacturing, and sales of precision components and products for medical devices, with key products including home ventilator components, cochlear implant components, and pulmonary function instruments [3][8]. - The revenue composition of the company includes 59.48% from home ventilator components, 14.61% from home and consumer electronics components, 10.33% from other medical product components, 8.16% from cochlear implant components, and 5.63% from precision molds and automation equipment [8]. Group 2: Financial Performance - For the period from January to September 2025, the company achieved a revenue of 1.194 billion yuan, representing a year-on-year growth of 3.28%, while the net profit attributable to the parent company was 208 million yuan, showing a year-on-year decrease of 19.25% [9]. - The company's overseas revenue accounted for 86.64% of total revenue, benefiting from the depreciation of the RMB [4]. Group 3: Market Activity - On January 14, the company's stock price fell by 2.32%, with a trading volume of 1.332 billion yuan and a turnover rate of 9.79%, resulting in a total market capitalization of 20.383 billion yuan [1]. - The main capital inflow for the day was -116 million yuan, indicating a reduction in main capital positions over the past two days [5][6]. Group 4: Shareholder Information - As of December 19, the number of shareholders was 15,300, a decrease of 1.74% from the previous period, with an average of 24,335 circulating shares per person, an increase of 1.77% [9][10]. - The second-largest circulating shareholder is Guotai Junan Value Advantage Flexible Allocation Mixed Fund, holding 5.9179 million shares, while several new shareholders have entered the top ten list [10].

Core Viewpoint - Meihua Medical's stock price has shown significant volatility, with a year-to-date increase of 55.59% but a recent decline of 9.96% over the past five trading days [2]. Group 1: Stock Performance - As of January 14, Meihua Medical's stock price was 37.42 CNY per share, with a market capitalization of 21.287 billion CNY [1]. - The stock has experienced a 77.68% increase over the past 20 days and a 67.58% increase over the past 60 days [2]. - The company has appeared on the "Dragon and Tiger List" twice this year, with the latest instance on January 7, where it recorded a net buy of -71.9649 million CNY [2]. Group 2: Financial Performance - For the period from January to September 2025, Meihua Medical reported a revenue of 1.194 billion CNY, reflecting a year-on-year growth of 3.28%, while the net profit attributable to shareholders decreased by 19.25% to 208 million CNY [3]. Group 3: Shareholder Information - As of December 19, the number of shareholders for Meihua Medical was 15,300, a decrease of 1.74% from the previous period, with an average of 24,335 circulating shares per shareholder, an increase of 1.77% [3]. - The company has distributed a total of 293 million CNY in dividends since its A-share listing [4]. - Notable institutional shareholders include Guotai Junan's value advantage flexible allocation fund and Huabao's medical ETF, with changes in their holdings noted [4].

截至2026年1月13日收盘，美好医疗(301363)报收于36.68元，下跌6.93%，换手率11.53%，成交量43.03 万手，成交额15.85亿元。 当日关注点 交易信息汇总资金流向 大宗交易 1月13日美好医疗现208.8万元大宗交易。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自交易信息汇总：1月13日主力资金净流出1100.79万元，游资资金净流出规模较大，达8272.92 万元，散户资金净流入9373.71万元。 来自交易信息汇总：1月13日美好医疗发生一笔208.8万元的大宗交易。 1月13日主力资金净流出1100.79万元；游资资金净流出8272.92万元；散户资金净流入9373.71万元。 ...

1月13日，美好医疗收跌6.93%，收盘价为36.68元，发生1笔大宗交易，合计成交量5.8万股，成交金额 208.8万元。 第1笔成交价格为36.00元，成交5.80万股，成交金额208.80万元，溢价率为-1.85%，买方营业部为国泰 海通证券股份有限公司深圳福田中心区华融大厦证券营业部，卖方营业部为国泰海通证券股份有限公司 深圳海岸城海德三道证券营业部。 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 进一步统计，近3个月内该股累计发生1笔大宗交易，合计成交金额为208.8万元。该股近5个交易日累计 上涨5.92%，主力资金合计净流出3.8亿元。 责任编辑：小浪快报 ...

Core Insights - The brain-computer interface (BCI) industry in China is experiencing significant advancements, with clinical results emerging for high-level paraplegics and substantial funding rounds, including a recent 2 billion yuan investment in a non-invasive unicorn company, Strong Brain Technology, marking the second-largest funding record globally in this field [1][2] - The industry is poised for rapid commercialization, driven by technological breakthroughs, capital influx, and supportive policies, as it transitions from cutting-edge technology to practical applications in daily life [1][5] Technological Breakthroughs - Recent advancements in BCI technology include successful clinical trials for invasive systems, enabling high-level paraplegics to control smart wheelchairs and robotic dogs [2][3] - Companies like JieTi Medical and Chip Intelligence have made significant progress, with JieTi completing trials for its invasive BCI system and Chip Intelligence's semi-invasive product achieving human implantation [2][3] - The first clinical trial of a fully implanted, wireless BCI product by Brain Tiger Technology has shown promising results, allowing an 8-year paraplegic patient to achieve thought control just five days post-surgery [2][3] Policy and Capital Support - The BCI sector benefits from comprehensive policy support, including its designation as one of the six future industries in the 14th Five-Year Plan, which elevates it to a national strategic priority [5][6] - Recent initiatives by the Sichuan provincial medical insurance bureau have established pricing for 82 neuro-related medical services, including BCI applications, facilitating clinical adoption [5][6] - The establishment of industry standards by the National Medical Products Administration is expected to lower costs and risks associated with technology development and clinical application [6] Industry Collaboration and Investment - Companies like Baiyang Pharmaceutical are actively collaborating with academic institutions to explore the integration of BCI with artificial intelligence, aiming for innovative clinical solutions [7] - Other listed companies are also engaging in the BCI space through material supply and equipment development, indicating a strong interest from institutional investors [7] Future Development and Challenges - The BCI industry is anticipated to move towards standardization and scalability, with initial industry standards expected to be established by 2027-2028 [8] - Potential constraints include the pace of chip design and production, as well as the need for ethical regulations regarding personal brain data [8] - Despite these challenges, the domestic BCI industry holds significant advantages, including strong policy support, a vast clinical resource base, and a comprehensive supply chain [8] Investment Opportunities - The BCI sector presents a dual investment opportunity in both medical and technological domains, with short-term focus on disease treatment and long-term potential for enhancing human capabilities through integration with AI and robotics [9] - The industry is positioned to cultivate leading global BCI companies, fostering a capital-innovation synergy between primary and secondary markets [9]

Group 1 - The Chinese government has adjusted the export tax rebate policy for photovoltaic and battery products, reducing the VAT export rebate rate for battery products from 9% to 6% starting April 1, 2026, and fully canceling it by January 1, 2027, with a three-month transition period [2] - The purpose of the policy adjustment is to compress the profit margins of low-value-added production, encourage companies to transition to high-value-added products, and guide enterprises to establish overseas production to mitigate geopolitical risks [2][3] - The lithium carbonate futures market has seen a significant increase, with the main contract closing at 156,060 yuan per ton, marking a 9% increase and the first time surpassing the 150,000 yuan mark in two years, driven by policy changes and improved fundamentals [2] Group 2 - In the photovoltaic sector, companies are expected to accelerate order deliveries during the transition period, leading to a significant increase in export growth in the first quarter of 2026, particularly benefiting leading companies with high export ratios [3] - From 2027 onwards, industry differentiation is expected to intensify, with overseas production capacity becoming a core competitive advantage for leading companies like CATL, BYD, and LONGi, as domestic production costs will rise by 6-9% due to the cancellation of tax rebates [3] - The exit of outdated production capacity is anticipated to significantly increase industry concentration, with the top five companies expected to exceed 80% market share by 2027, enhancing pricing power and overall profitability in the industry [3] Group 3 - The Federal Reserve Chairman Jerome Powell is under criminal investigation related to the renovation of the Federal Reserve's headquarters, which has escalated tensions with former President Trump, who has previously criticized Powell for not lowering interest rates [4][5] - Powell described the investigation as unprecedented and questioned its motives, asserting that he would not succumb to political pressure while fulfilling his duties [4][5][7] Group 4 - Gold and silver prices have surged, with gold surpassing $4,600 and silver exceeding $83, driven by increased geopolitical risks and expectations of interest rate cuts following poor non-farm payroll data [8][9] - The U.S. government is considering various options to intervene in Iran, including military actions, which has contributed to rising demand for safe-haven assets like gold [8][9] Group 5 - ByteDance has significantly increased its investment in data centers, with a capital expenditure budget of approximately 160 billion yuan for 2025, including nearly 70 billion yuan specifically for data center infrastructure and network equipment [10][11] - The bidding activity for AI data centers has accelerated, with major projects like a 1 GW project already announced, indicating a robust demand surge starting in the fourth quarter of 2025 [11][14] - The improvement in AI chip supply, particularly the easing of export restrictions on NVIDIA's H200 chips, has facilitated the resumption of data center construction plans that were previously hindered by chip shortages [12][15] Group 6 - The domestic AI data center bidding landscape is expected to benefit from the scarcity of resources, with operators possessing high-quality resources having a stronger ability to fulfill orders and maintain pricing power [19] - The preference for bidding is concentrated in regions with lower electricity costs, such as Inner Mongolia and Shanxi, which will significantly reduce operational costs for data centers [19] - The domestic liquid cooling sector is poised for recovery as demand from AI data centers exceeds expectations, benefiting local manufacturers closely tied to major internet companies [18]